

17th International Forum on Mood and Anxiety Disorders

www.ifmad.org



Final Programme

Siegfried **KASPER** (Austria), Stuart A. **MONTGOMERY** (UK),
Allan H. **YOUNG** (UK), Eduard **VIETA** (Spain)

Madrid (*Spain*)
14-16 December 2017





Scientific Committee

Chairmen

Siegfried Kasper (Austria) - Stuart Montgomery (United Kingdom) – Eduard Vieta (Spain) – Allan Young (United Kingdom)

Scientific Advisers

C.A. Altamura (Italy), D. Baldwin (United Kingdom), B. Bandelow (Germany), M. Bauer (Germany), T. Dinan (Ireland), E. Eriksson (Sweden), N. Fineberg (United Kingdom), S.H. Kennedy (Canada), D. Lecic Tosevski (Serbia), A.A. Mathé (Sweden), H.J. Möller (Germany), S. Pallanti (Italy), J. Raboch (Czech Republic), Z. Rihmer (Hungary), A. Serretti (Italy), D.J. Stein (South Africa), T. Svensson (Sweden), D. Winkler (Austria), S. Yamawaki (Japan), J. Zohar (Israel)

Important Addresses

ORGANIZING SECRETARIAT:



PUBLI CRÉATIONS - 74, Bd d'Italie - 98000 Monte-Carlo - Monaco

Ph. +377 97973555 - Fax +377 97973550

Publi Créations

E-mail: ifmad@publiccreations.com - Website: <http://www.ifmad.org/2017/>

CONGRESS VENUE:



ATENEO DE MADRID

Ateneo de Madrid - Calle del Prado, 21, 28014 Madrid, Spain

Tel: +34 914 29 62 51



Welcome Letter

Dear Colleagues, dear Friends,

It is with a great pleasure that we welcome you to the 17th International Forum on Mood and Anxiety Disorders (IFMAD 2017) that will be taking place this year on December 14– 16th in Madrid!

IFMAD has developed the reputation over many years of being the most interactive, stimulating and productive educational meeting in its field in Europe and since 2015 we are providing an even more comprehensive scientific and educational programme.

It is accredited for continuing medical education. In a friendly atmosphere difficult clinical challenges are dissected, discussed and reformulated with high ranking experts to achieve the best evidence based path to treatment in depression, anxiety and bipolar disorder. To avoid bias, our educational program is completely independent from pharmaceutical support.

IFMAD 2017 topics will include: Update on rapid acting antidepressants, Treatment adherence, Cognition in Mood Disorders, Update on treatment of Anxiety Disorders, Advances in treatment of resistant depression, Biomarkers for Mood Disorders, Long acting antipsychotics in Bipolar Disorder, Update on psychoneuroimmunology, Overlap of negative symptoms and depression, Anxiety Disorder spectrum, Brain gut interactions.

We look forward to seeing you all in Madrid for IFMAD 2017, to building strong professional contacts an expanding international network, to welcoming new participants and meeting our old friends, and discussing together the most important issues in this area of medicine!

The IFMAD Chairmen



Siegfried Kasper



Stuart A. Montgomery



Allan H. Young



Eduard Vieta



Acknowledgements

The Organizing Committee express their gratitude

in supporting the poster presenters

to

KARGER

Medical and Scientific Publishers

and



iMADRID!

Madrid Convention Bureau

for their contribution to the Congress



SCIENTIFIC PROGRAMME - Thursday, 14 DECEMBER 2017

14.30 – 16.30 SO 01. SCIENTIFIC SESSION - CHAIRS: S. KASPER, S. MONTGOMERY

14.30 – 15.00 SO 0101. Depression, the Epidemic

Jose Luis Ayuso (Spain)

15.00 – 15.10 *Discussion*

15.10 – 15.40 SO 0102. Advances in the prevention of suicidality

Zoltan Rihmer (Hungary)

15.40 – 15.50 *Discussion*

15.50 – 16.20 SO 0103. Positive and negative brain gut interactions

Timothy Dinan (Ireland)

16.20 – 16.30 *Discussion*

16.30 – 17.50 SO 02. SCIENTIFIC SESSION - CHAIRS: A. YOUNG, T. DINAN

16.30 – 17.00 SO 0201. How should we treat primary negative symptoms in schizophrenia?

Istvan Bitter (Hungary)

17.00 – 17.10 *Discussion*

17.10 – 17.40 SO 0202. Does response in secondary negative symptoms provide any evidence of efficacy on primary negative symptoms in schizophrenia?

Hans-Jürgen Möller (Germany)

17.40 – 17.50 *Discussion*

18.00–19.00 OPENING COCKTAIL



SCIENTIFIC PROGRAMME - Friday, 15 DECEMBER 2017

08.30 – 10.30 SO 03. SCIENTIFIC SESSION - CHAIRS: : A. YOUNG, H. J. MÖLLER

08.30 – 09.00 SO 0301. The treatment of OCD Spectrum Disorder

Naomi Fineberg (United Kingdom)

09.00 – 09.10 *Discussion*

09.10 – 09.40 SO 0302. Update on treatment of anxiety disorders

David Baldwin (United Kingdom)

09.40 – 09.50 *Discussion*

09.50 – 10.20 SO 0303. Managing resistance to treatment in anxiety disorders

Borwin Bandelow (Germany)

10.20 – 10.30 *Discussion*

10.30–11.00 COFFEE BREAK

11.00 – 12.20 SO 04. SCIENTIFIC SESSION - CHAIRS: D. BALDWIN, B. BANDELOW

11.00 – 11.30 SO 0401. Advances in personalised treatment of depression

Alessandro Serretti (Italy)

11.30 – 11.40 *Discussion*

11.40 – 12.10 SO 0402. Eskatamine in rapid response and long term treatment of resistant depression?

Siegfried Kasper (Austria)

12.10 – 12.20 *Discussion*

12.20–13.00 DISCUSSION OF THE ON-LINE SURVEY

13.00–14.30 LUNCH



SCIENTIFIC PROGRAMME - Friday, 15 DECEMBER 2017

14.30 – 16.30 SO 05. SCIENTIFIC SESSION - CHAIRS: A. SERRETTI, F. DRAGO

14.30 – 15.00 SO 0501. Managing Bipolar Disorder and Comorbid ADHD

Carmen Moreno (Spain)

15.00 – 15.10 *Discussion*

15.10 – 15.40 SO 0502. The Role of long acting injectable antipsychotics in Bipolar Disorder

Eduard Vieta (Spain)

15.40 – 15.50 *Discussion*

15.50 – 16.20 SO 0503. Update on lithium

Allan Young (United Kingdom)

16.20 – 16.30 *Discussion*

16.30–17.00 COFFEE BREAK

17.00 – 18.20 SO 06. SCIENTIFIC SESSION - CHAIRS: A. KAUTZKY, E. VIETA

17.00 – 17.30 SO 0601. The affective domain in schizophrenia, more than an epiphenomenon. Therapeutic implications

Celso Arango (Spain)

17.30 – 17.40 *Discussion*

17.40 – 18.10 SO 0602. Are the criteria for licensing treatments in psychiatry in Europe too complex?

Filippo Drago (Italy)

18.10 – 18.20 *Discussion*



SCIENTIFIC PROGRAMME - Saturday, 16 DECEMBER 2017

08.30 – 09.15 STROLLING POSTER SESSION

09.15 – 10.30 SO 07. SCIENTIFIC SESSION - CHAIRS: C. ARANGO, J. ZOHAR

09.15 – 09.45 SO 0701. Which are the most important clinical predictors of treatment resistance in depression

Alexander Kautzky (Austria)

09.45 – 09.50 Discussion

09.50 – 10.20 SO 0702. Genetic pathways to response and resistance in depression

Chiara Fabbri (Italy)

10.20 – 10.30 Discussion

10.30 – 11.50 SO 08. SCIENTIFIC SESSION - CHAIRS: S. MONTGOMERY, C. FABBRI

10.30 – 11.00 SO 0801. Advances in treatment of sleep disorders

Göran Hajak (Germany)

11.00 – 11.10 Discussion

11.10 – 11.40 SO 0802. What not to do in treating PTSD

Joseph Zohar (Israel)

11.40 – 11.50 Discussion

11.50–12.15 CLOSING REMARKS & POSTER AWARD

12.15–12.45 FAREWELL COFFEE



Posters

P.01 Assessment of depression, anxiety & stress symptoms in caregivers of psychiatric patients

Surabhi Agarwal; Jyoti Shetty; Arun Singh

Bharati Hospital, Bharati Vidyapeeth deemed University & Medical College, Pune, India

P.02 Subjective efficacy of repetitive transcranial magnetic stimulation in pharmacoresistant depressive episodes occurring in various mental disorders: clinical observation study

Jakub Albrecht; Tadeáš Mareš; Katarína Jaššová; Jiří Raboch; Martin Anders

Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Rep.

P.03 Manic symptoms in a bubble

Margarida Albuquerque¹; Daniel Esteves de Sousa¹; Miguel Costa¹; Sérgio Gomes Pereira²; Pedro Cintra¹

¹*Departamento de Psiquiatria e Saúde Mental, Hospital de Cascais, Cascais, Lisboa, Portugal;*

²*Departamento de Psiquiatria e Saúde Mental, Hospital Egas Moniz, Lisboa, Portugal*

P.04 Punishment and reward sensitivity in young people with depressive symptomatology

Alexandra Antonesej; Kou Murayama; Ciara McCabe

University of Reading, School of Psychology, Reading, United Kingdom

P.05 Comparison of inflammation and grey matter volume between patients with unipolar depression and bipolar disorder

Ya Mei Bai; Pei-Chi Tu; Mu-Hong Chen; Ju-Wei Hsu; Kei-Lin Huang

Department of Psychiatry, National Yang-Ming University and Taipei Veterans General Hospital, Taiwan, Taipei, Taiwan (China)

P.06 The EEG predictors and early change of depressive symptoms in the prediction of treatment outcome in patients suffering from depressive disorder

Martin Bares^{1,2}; Martin Brunovsky^{1,2}; Tomas Novak^{1,2}; Premysl Vlcek¹; Martin Hejzlar^{1,2}

¹*National Institute of Mental Health Czech Republic, Klecany, Czech Rep.;*

²*Department of Psychiatry and Medical Psychology, 3rd Medical Faculty, Charles University, Prague, Czech Rep.*



Posters

P.07 Vitamin D in autistic children and depressive adults

Marie Bicikova¹; Ludmila Macova¹; Daniela Ostatnikova²; Bozena Kalvachova¹

¹*Institute of Endocrinology, Prague, Czech Rep.;*

²*Institute of Physiology, Faculty of Medicine, Bratislava, Slovakia*

P.08 Effects of repeated COX-2 inhibitor administration on synaptic transmission and plasticity in mice cortex and hippocampus

Bartosz Bobula¹; Grzegorz Hess^{1,2}; Katarzyna Stachowicz³; Magdalena Sowa-Kućma^{3,4}; Tomasz Lenda⁵; Paulina Misztak^{3,6}; Paulina Pańczyszyn-Trzewik³; Gabriel Nowak^{3,6}; Andrzej Pilc³

¹*Institute of Pharmacology, Polish Academy of Sciences, Department of Physiology, Kraków, Poland;*

²*Institute of Zoology, Jagiellonian University, Kraków, Poland;*

³*Institute of Pharmacology, Polish Academy of Sciences, Department of Neurobiology, Kraków, Poland;*

⁴*Department of Human Physiology, Institute of Clinical and Experimental Medicine, Medical Faculty, University of Rzeszów, Rzeszów, Poland;*

⁵*Institute of Pharmacology, Polish Academy of Sciences, Department of Neuropsychopharmacology, Kraków, Poland;*

⁶*Jagiellonian University Medical College, Department of Pharmacobiology, Kraków, Poland*

P.09 Cognitive functioning after acute cardiac events: the role of mental fatigue

Julius Burkauskas¹; Adomas Bunevicius²; Julija Brozaitiene¹; Naomi A. Fineberg³; David Wellsted⁴; Robertas Bunevicius¹; Narseta Mickuviene¹

¹*Behavioral Medicine Institute, Lithuanian University of Health Sciences, Palanga, Lithuania;*

²*Institute of Neurosciences, Laboratory of Clinical Research, Lithuanian University of Health Sciences, Kaunas, Lithuania;*

³*National Obsessive Compulsive Disorders Specialist Service, Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, United Kingdom;*

⁴*Centre for Lifespan and Chronic Illness Research, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom*

Posters

P.10 Monitorization after hospital psychiatric consultation among patients with mood and anxiety disorders

Ana Calle

Hospital 12 de Octubre, Madrid, Spain

P.11 What difference does screening make in postnatal depression?

Tze-Ern Chua; Beverly Chia; Jintana Tang; Helen Chen

Department of Psychological Medicine, KK Women's & Children's Hospital, SG, Singapore

P.12 Early environmental enrichment restores neurotrophin-3 underexpression and compensates for the anxiety-like behavior induced by prenatal stress-hypercortisolemia in the cerebellar cortex of adolescent offspring

Isabel Cuevas; Martina Valencia; Javiera Illanes; Rodrigo Pascual

Laboratorio de Neurociencias Escuela de Kinesiología Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile

P.13 A comparison of the United States food and drug administration (FDA) approval process, the european medicines agency (EMA) approval process, and the approval process in Asia in 2017

Pia Alexis Fernandez¹; Francisco Javier Fletes²

¹*University of Makati, Makati, Philippines;*

²*Tripler Army Medical Center, Honolulu, USA*

P.14 Electroconvulsive therapy use in the presence of intracranial metallic objects

Ana Sofia Ferreira; David Mota; Filipe Almeida; Joana Andrade

Coimbra Hospital and University Centre (CHUC), Coimbra, Portugal

P.15 Patterns of depressive symptoms among persons in very late life in Jamaica

Roger Gibson; Kenneth James; Norman Waldron; Wendel Abel; Denise Eldemire-Shearer; Kathryn Mitchell-Fearon

The University of the West Indies, Kingston, Jamaica

Posters

P.16 The effect of suicide prevention for depression people with narrative nursing

Masami Hasegawa

Niigata College of Nursing, Jyousetsu, Japan

P.17 "Don't look back" - Post-event processing in test anxiety

Sarah Kahl; Rapoport Rapoport; Eva Neidhardt

University Koblenz-Landau, Campus Koblenz, Koblenz, Germany

P.18 Influence of high level of psychological vulnerability factors to bipolar disorders on a semantic mediated priming task

Mélanie Labalestra^{1,2}; Nicolas Stefaniak²; Laurent Lefebvre¹; Chrystel Besche-Richard²

¹*Service de Psychologie Cognitive et Neuropsychologie, Université de Mons, Mons, Belgium;*

²*Laboratoire Cognition, Santé, Socialisation - C2S, EA6291, Université de Reims Champagne-Ardenne, Reims, France*

P.19 Prevalence of DSM-IV major mental disorders among North Korean defectors in South Korea

Kyoung Eun Lee¹; Ji Hyun An¹; Hyo Chul Lee¹; Hae Soo Kim¹; Hye In Chang²; Jin Pyo Hong¹

¹*Department of Psychiatry, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, South;*

²*Department of Psychology, Sungkyunkwan University, Seoul, Korea, South*

P.20 Towards the improvement of cognitive insight in bipolar disorder

Van Camp Lynn^{1,2}; Oldenburg Jonne^{1,2}; Sabbe Bernard^{1,2}

¹*Collaborative Antwerp Psychiatric Research Institute (CAPRI), Antwerp, Belgium;*

²*Psychiatric Hospital Duffel, University Department, Antwerp, Belgium*

P.21 Bipolar affective disorder and Parkinson's disease: a rare association?

Pedro Macedo; Figueiredo Ana Rita; Fornelos Antónia; Roque Marta

Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal

Posters

P.22 Delirious mania: a case report

Ana Luzia Melo; Filipe Godinho; Sofia Marques; Daniel Barrocas; Madalena Serra
Hospital do Espírito Santo de Évora, Évora, Portugal

P.23 Effect of chronic Imipramine with NS-398 (COX-2 inhibitor) injection on the level of BDNF in Hippocampus and Prefrontal Cortex of C57Bl/6J mice

Paulina Misztak^{1,2}; Patrycja Pańczyszyn-Trzewik¹; Magdalena Sowa-Kućma^{1,3}; Andrzej Pilc¹; Gabriel Nowak^{1,2}; Katarzyna Stachowicz¹

¹*Department of Neurobiology, Institute of Pharmacology, Polish Academy of Science, Krakow, Poland;*

²*Department of Pharmacobiology, Jagiellonian University Medical College, Krakow, Poland;*

³*Department of Human Physiology, Institute of Clinical and Experimental Medicine, Medical Faculty, University of Rzeszow, Rzeszow, Poland*

P.24 Cognitive functioning in child and adolescent offspring of parents with bipolar disorder

Tomas Novak¹; Antonin Sebel¹; Marketa Mohaplova²; Michaela Viktorinova¹; Michal Goetz²

¹*National Institute of Mental Health, Klecany, Czech Rep.;*

²*Department of Paediatric Psychiatry, Motol University Hospital, Prague, Czech Rep.*

P.25 Switching between different modalities of Electroconvulsive Therapy (ECT): A naturalistic observational study in Singapore

Li Keat Oon; Hatta Santoso Ong; Phern Chern Tor
Institute of Mental Health (IMH), Singapore, Singapore

P.26 Prenatal stress alters the expression synaptic proteins and anxiety-like behavior in adolescent offspring

Jose Pascual; Martina Valencia; Javiera Illanes; Isabel Cuevas *Neuroscience Laboratory, School of Kinesiology, Faculty of Sciences, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile*

P.27 Prevalence of depression among patients with cerebrovascular accidents- in a stroke unit of a developing country

Sumudu Rajapakse¹; Varuni De Silva²; Padma Gunarathne²

¹*The Townsville Hospital, Townsville, Australia;*

²*National Hospital Sri Lanka, Colombo, Sri Lanka*



Posters

P.28 The benefits of worrying - new findings in test anxiety and procrastination

Olga Rapoport; Sarah Kahl; Eva Neidhardt

University of Koblenz-Landau, Koblenz, Germany

P.29 Assessment of depression & anxiety associated with dermatological conditions

Arun Sain; Surabhi Agarwal; Jyoti Shetty

Bharati Hospital, Bharati Vidyapeeth deemed University & Medical College, Pune, Pune, India

P.30 Shahin mixed depression scale (SMDS); a novel tool that captures unofficial mixity in depression

Islam Shahin

Shahin Mood Disorder clinics, Cairo, Egypt

P.31 Long acting injectable antipsychotics in bipolar disorder: a 2-year prospective cohort study

Carla Spínola¹; Daniel Neto^{1,2}; Maria Emília Pereira¹; Joaquim Gago^{1,2}

¹*Department of Mental Health - Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal;*

²*NOVA Medical School - UNL, Lisboa, Portugal*

P.32 Changes in serotonin and noradrenaline level in C57Bl/6J mice brain after chronic co-treatment of imipramine with NS398 (COX-2 inhibitor)

Katarzyna Stachowicz¹; Magdalena Sowa-Kućma^{1,2}; Tomasz Lenda³; Paulina Misztak^{1,4}; Patrycja Pańczyszyn-Trzewik¹; Gabriel Nowak^{1,4}; Andrzej Pilc¹

¹*Institute of Pharmacology, Polish Academy of Sciences, Department of Neurobiology, Krakow, Poland;*

²*Department of Human Physiology, Institute of Clinical and Experimental Medicine, Medical Faculty, University of Rzeszow, Rzeszow, Poland;*

³*Institute of Pharmacology, Polish Academy of Sciences, Department of Neuropsychopharmacology, Krakow, Poland;* ⁴*Jagiellonian University Medical College, Department of Pharmacobiology, Krakow, Poland*

Posters

P.33 Clinical psychopathological and pathopsychological features of suicide among women

Fidan Suleymanli¹; Nasimi Vahabov²; Ramil Huseynzade¹; Orkhan Isgandarov¹; Nargiz Mushtagzade¹

¹Azerbaijan Medical University, Baku, Azerbaijan

²Department of Psychiatry, Azerbaijan Medical University

P.34 Alcohol consumption in Austrian medical doctors

Dietmar Winkler; Alexander Pfaffeneder; Siegfried Kasper; Edda Pjrek

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

P.35 Seasonal prescription pattern of antidepressant medication

Edda Winkler-Pjrek¹; Reichardt Berthold²; Georg S. Kranz¹; Siegfried Kasper¹; Dietmar Winkler¹

¹Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria;

²Sickness Fund Burgenland (BGKK), Eisenstadt, Austria

P.36 Behavioural effects of high fat diet in early adulthood in Nrg1 transmembrane domain mutant mice

Jerzy Zieba^{1,2,3}; Margaret J Morris²; Tim Karl^{1,2,3,4}

¹Neuroscience Research Australia, NSW 2031, Sydney, Australia;

²School of Medical Sciences, University of New South Wales, NSW 2052, Sydney, Australia;

³Schizophrenia Research Institute, NSW 2031, Sydney, Australia;

⁴School of Medicine, Western Sydney University, NSW 2560, Sydney, Australia



Scientific Information

Audio-Visual

Equipment for computerized Power Point presentation is provided during the scientific sessions. Power Point presentations, CD-Rom or USB keys can be viewed and tested prior to presentation at the Speakers' Corner and must be handed over to the room technicians at least forty minutes before the beginning of the sessions and collected directly by the speakers immediately after. It is essential for the smooth running of the sessions that all Speakers hand in their presentation in due time.

European Accreditation

The IFMAD congress has been granted with 12 European CME credits by the European Accreditation Council for Continuing Medical Education (EACCME) and these credits are recognized by the American Medical Association for conversion to AMA PRA Category 1 Credit.



Certificate of Attendance

A certificate of attendance is provided by e-mail after the Congress.

Posters

The selected abstracts for poster display (at a maximum height of 150 cm and 90 cm base) are displayed at the Ateneo de Madrid from **Thursday, 14 December 2017** to **Saturday, 16 December 2017**. Poster material must be prepared in advance and should be large enough to be viewed at a distance of 2 m. Drawings and charts should be clear and simple. Posters should be attended by the authors themselves, in order to view and discuss them during lunchtime and coffee breaks and a special poster session is scheduled on Saturday from 08.30 to 09.15. The Best Posters will be selected by the Scientific Committee and the Poster Prizes will be announced during the final wrap up at 11.50 on 16 December 2017.



General Information

The “17th International Forum on Mood and Anxiety Disorders” is held at the Ateneo de Madrid on 14-16 December 2017.

Admission

The participant's name badge is provided at the registration desk. All participants are requested to wear the badge throughout the congress. Only badge holders are admitted to the appropriate sessions and Opening Reception.

Language

The official language of the Congress is English. No simultaneous translation is provided.

Insurance

The Congress organizers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress. Registration does not include insurance. It is strongly recommended that you take an insurance policy of your choice as you register for the Congress and book your travel.

Secretariat

The secretariat desk will open on Thursday, 14 December at 11h00 and stay open all through the Congress, Saturday 16 December at 12h45.

Welcome cocktail

All delegates are cordially invited to attend the Opening Reception which will be held on **Thursday, 14 December** at the Ateneo de Madrid at **18.00**.



IFMAD

www.ifmad.org

17th **International Forum
on Mood and Anxiety Disorders**

Madrid
14-16 December 2017



Publi Créations

74, Bd d'Italie - 98000 Monte-Carlo - Monaco

Ph. +377 97 97 35 55 - Fax +377 97 97 35 50

E-mail: ifmad@publiccreations.com